IMGN ImmunoGen Inc.

-0.05  -3%
Previous Close 1.87
Open 1.89
Price To Book -10.11
Market Cap 272,146,322
Shares 149,530,946
Volume 4,943,177
Short Ratio
Av. Daily Volume 3,869,709

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved Feb 22 2013 - under priority review
2nd-line HER2+ Metastatic Breast Cancer
Phase 1b/2 presentation at ASCO June 1, 2019.
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer
Phase 3 top-line data released March 1, 2019 did not meet primary endpoint. Further Phase 3 trial required (noted May 15, 2019).
Mirvetuximab soravtansine - FORWARD I
Cancer - ovarian cancer and relapsed endometrial cancer
Phase 3 trial did not meet endpoints.
Kadcyla KRISTINE trial
HER2-positive breast cancer - neo-adjuvant setting
Endpoint not met - October 2015
Kadcyla GATSBY trial
Cancer - metastatic HER2+ gastric cancer
Phase 3 data due in 2020.
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
Phase 3 data released Dec 18 2014. Met non-inferiority endpoint but did NOT significantly improve PFS compared to Herceptin and chemotherapy
Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) - Kadcyla - MARIANNE trial
Cancer - 1st-line HER2+ Metastatic Breast Cancer
Phase 1 updated data due 2019.
Acute Myeloid Leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Phase 1 additional data due at ASH December 1, 2018 noted 26% ORR; 7% CR.
Relapsed/refractory acute myeloid leukemia (AML)